TEVA-LISINOPRIL/HCTZ (TYPE P) TABLET

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

LISINOPRIL (LISINOPRIL DIHYDRATE); HYDROCHLOROTHIAZIDE

Dostupno od:

TEVA CANADA LIMITED

ATC koda:

C09BA03

INN (International ime):

LISINOPRIL AND DIURETICS

Doziranje:

10MG; 12.5MG

Farmaceutski oblik:

TABLET

Sastav:

LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG; HYDROCHLOROTHIAZIDE 12.5MG

Administracija rute:

ORAL

Jedinice u paketu:

30/100

Tip recepta:

Prescription

Područje terapije:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Proizvod sažetak:

Active ingredient group (AIG) number: 0222417003; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2010-12-08

Svojstava lijeka

PRODUCT MONOGRAPH
PR
TEVA-LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin Converting Enzyme Inhibitor/Diuretic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Control No: 169889
Date of Preparation:
November 26, 2010
Date of Revision:
January 21, 2014
TEVA-LISINOPRIL/HCTZ (TYPE P) Tablets
2
PRODUCT MONOGRAPH
Pr
TEVA-LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin-Converting Enzyme Inhibitor/Diuretic
ACTION AND CLINICAL PHARMACOLOGY
TEVA-LISINOPRIL/HCTZ (TYPE P) (lisinopril and hydrochlorothiazide
tablets) combines the
action of an angiotensin-converting enzyme (ACE) inhibitor,
lisinopril, and a diuretic,
hydrochlorothiazide.
LISINOPRIL
Angiotensin-converting enzyme (ACE) is a peptidyl dipeptidase which
catalyzes the conversion
of angiotensin I to the pressor substance, angiotensin II. Inhibition
of ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum potassium. In patients
treated with lisinopril plus a
thiazide diuretic, there was essentially no change in serum potassium
(see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system,
lisinopril also lowers blood pressure
in patients with low-renin hypertension.
PHARMACODYNAMICS
LISINOPRIL
Administration of lisinopril to patients with hypertension results in
a reduction of both supine
and standing blood pressure. Abrupt withdrawal of li